» Articles » PMID: 16540641

Hypoxic Culture Induces Expression of Sialin, a Sialic Acid Transporter, and Cancer-associated Gangliosides Containing Non-human Sialic Acid on Human Cancer Cells

Overview
Journal Cancer Res
Specialty Oncology
Date 2006 Mar 17
PMID 16540641
Citations 82
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor hypoxia figures heavily in malignant progression by altering the intracellular glucose metabolism and inducing angiogenic factor production, thus, selecting and expanding more aggressive cancer cell clones. Little is known, however, regarding hypoxia-induced antigenic changes in cancers. We investigated the expression of N-glycolyl sialic acid (NeuGc)-G(M2), a cancer-associated ganglioside containing non-human sialic acid, NeuGc, in human cancers. Cancer tissues prepared from patients with colon cancers frequently expressed NeuGc-G(M2), whereas it was virtually absent in nonmalignant colonic epithelia. Studies on cultured cancer cells indicated that the non-human sialic acid was incorporated from culture medium. Hypoxic culture markedly induced mRNA for a sialic acid transporter, sialin, and this accompanied enhanced incorporation of NeuGc as well as N-acetyl sialic acid. Transfection of cells with sialin gene conferred accelerated sialic acid transport and induced cell surface expression of NeuGc-G(M2). We propose that the preferential expression of NeuGc-G(M2) in cancers is closely associated with tumor hypoxia. Hypoxic culture of tumor cells induces expression of the sialic acid transporter, and enhances the incorporation of non-human sialic acid from the external milieu. A consequence of this is the acquisition of cancer-associated cell surface gangliosides, typically G(M2), containing non-human sialic acid (NeuGc), which is not endogenously synthesized through CMP-N-acetyl sialic acid hydroxylase because humans lack the gene for the synthetic enzyme. As hypoxia is associated with diminished response to radiotherapy and chemotherapy, NeuGc-G(M2) is a potential therapeutic target for hypoxic cancer cells.

Citing Articles

The Role of Non-Human Sialic Acid Neu5Gc-Containing Glycoconjugates in Human Tumors: A Review of Clinical and Experimental Evidence.

Blanco R, Munoz J Biomolecules. 2025; 15(2).

PMID: 40001556 PMC: 11853303. DOI: 10.3390/biom15020253.


Antibody-targeted T cells and natural killer cells for cancer immunotherapy.

Sutherland A, Parlekar B, Livingstone D, Medina A, Bernhard W, Garcia T J Nanobiotechnology. 2024; 22(1):640.

PMID: 39425222 PMC: 11488284. DOI: 10.1186/s12951-024-02898-3.


A systematic review reveals conflicting evidence for the prevalence of antibodies against the sialic acid 'xenoautoantigen' Neu5Gc in humans and the need for a standardised approach to quantification.

Hutton E, Scott E, Robson C, Signoret N, Fascione M Front Mol Biosci. 2024; 11:1390711.

PMID: 38737334 PMC: 11082328. DOI: 10.3389/fmolb.2024.1390711.


Chimeric antigen receptor T cells targeting the GM3(Neu5Gc) ganglioside.

Heinzelbecker J, Fauskanger M, Jonson I, Krengel U, Loset G, Munthe L Front Immunol. 2024; 15:1331345.

PMID: 38370401 PMC: 10869436. DOI: 10.3389/fimmu.2024.1331345.


Distinct Metabolic Profiles of Ocular Hypertensives in Response to Hypoxia.

Langbol M, Rovelt J, Saruhanian A, Saruhanian S, Tiedemann D, Baskaran T Int J Mol Sci. 2024; 25(1).

PMID: 38203366 PMC: 10779258. DOI: 10.3390/ijms25010195.